LAS VEGAS - Feb. 26, 2026 - PRLog -- Cardiff Lexington Corporation (Stock Symbol: CDIX) is not quietly building a healthcare platform — it is executing an aggressive, measurable expansion strategy in some of the highest-demand medical verticals in the country: orthopedics, spine care, and pain management.
With triple-digit quarterly growth, expanding margins, new procedural hires, and a fully engaged Nasdaq uplisting strategy, CDIX is positioning itself as a scalable middle-market healthcare consolidator in a fragmented, high-margin sector.
Explosive Financial Performance Validates the Model
CDIX's third quarter 2025 results demonstrate operating leverage kicking in — and hard.
Q3 2025 vs Q3 2024:
- Revenue up 125.6% to $3.1 million
- Gross profit up 437.8% to $1.9 million
- Gross margins expanded to 62.4%
- Income from continuing operations surged 209.9% to $643,000
- Swing from operating loss to strong profitability
SG&A as a percentage of revenue dropped significantly, reflecting improving operational efficiency as scale increases.
Year-to-Date 2025 Performance:
- Revenue up 70.2% to $8.8 million
- Gross profit up 126.2% to $5.4 million
- Operating income of $1.8 million vs. prior-year loss
- Total assets increased 15.4% to $27.6 million
This is what disciplined expansion looks like: revenue growth, margin expansion, and profitability scaling simultaneously.
Nova Ortho and Spine: A Platform Built for Regional Dominance
All current CDIX revenue is derived from its operating subsidiary, Nova Ortho and Spine, LLC, which runs a growing network of specialty and ancillary orthopedic care centers across Florida and Georgia.
The model is straightforward and powerful:
- Acquire and scale middle-market niche clinics
- Focus on orthopedics, spine, and pain management
- Provide comprehensive diagnostic and surgical services
- Target traumatic injury and underserved patient populations
These facilities deliver:
- Primary care evaluations
- Interventional pain management
- Specialty consultations
- Orthopedic and spinal surgical procedures
In high-demand medical specialties with consistent patient need, procedural revenue and ancillary services create strong margin profiles.
Strategic Expansion into Underserved Florida Markets
In December, Nova Ortho and Spine performed its first procedures at Doctor's Memorial Hospital in Perry, Florida — marking an important milestone in expanding into underserved rural markets.
CEO Alex Cunningham emphasized the company's commitment to delivering best-in-class orthopedic and spinal care to regions historically lacking adequate specialty services.
This expansion model accomplishes two objectives simultaneously:
- Revenue growth through geographic expansion
- Community impact in medically underserved regions
The company has demonstrated the ability to mobilize quickly and deploy specialty services where demand already exists.
High-Caliber Clinical Talent Accelerates Growth
CDIX recently strengthened its Florida operations with two experienced, procedurally trained nurse practitioners:
- Catherine Amanda Kelly, MSN, APRN, FNP-BC – 20 years of experience in emergency, hospital, and procedural medicine.
- Ashley Logan, APRN-BC – Extensive background in neurosurgery, orthopedic surgery, and pain management.
These hires are not administrative additions — they directly support:
- Increased patient volume
- Procedural capacity expansion
- Operational efficiency improvements
- Higher patient satisfaction and throughput
As volume grows, clinical infrastructure scales accordingly.
N A S D A Q Uplist Strategy: Institutional Positioning in Motion
CDIX has publicly filed a Form S-1 with the U.S. Securities and Exchange Commission and intends to list on The Nasdaq Capital Market under the symbol "CDIX."
To execute this strategy, the company has engaged:
- R. F. Lafferty & Co., Inc. as sole bookrunning manager and strategic advisor
- Greentree Financial Group, Inc. to support corporate governance, audit processes, SEC responses, and public markets compliance
The company has also revised its stock structure to support Nasdaq minimum bid price compliance.
This is not exploratory — it is structured, deliberate, and professionally managed capital markets positioning.
A successful uplisting would:
- Increase visibility
- Expand institutional access
- Enhance liquidity
- Strengthen valuation comparability to peer healthcare platforms
A Disciplined Acquisition & Build Strategy in High-Demand Medical Verticals
CDIX is a targeted healthcare holding company focused on acquiring and building middle-market niche clinics in:
- Orthopedics
- Spine care
- Pain management
These specialties benefit from:
- Aging population tailwinds
- Consistent procedural demand
- Insurance-reimbursed services
- Opportunities for ancillary revenue streams
The company's partnership-driven culture emphasizes accountability, performance, and operational discipline — critical factors in successful healthcare roll-ups.
Why Investors Are Paying Attention
CDIX is demonstrating:
- Triple-digit quarterly growth
- Margin expansion above 60%
- Transition to operating profitability
- Expanding asset base
- Professional Nasdaq uplist strategy
- Geographic expansion into underserved markets
- Scalable specialty healthcare model
Few micro-cap healthcare operators show this combination of revenue acceleration, margin strength, operational discipline, and structured capital markets execution simultaneously.
The Bottom Line
Cardiff Lexington Corporation (CDIX) is executing on multiple fronts at once:
✔ Rapid revenue growth
✔ Expanding margins
✔ Clinical team expansion
✔ Rural market penetration
✔ Institutional-grade uplist strategy
✔ Scalable specialty healthcare consolidation model
As healthcare fragmentation continues and specialty demand rises, CDIX is positioning itself to scale into a significantly larger regional platform.
For investors seeking exposure to a fast-growing specialty healthcare consolidator with improving fundamentals and a clear Nasdaq trajectory, CDIX warrants serious attention.
For more information on CDIX visit: https://cardifflexington.com/
Media Contact:
Company Name: Cardiff Lexington Corporation (Stock Symbol: CDIX)
Contact: Alex Cunningham, CEO
Email: investorsrelations@cardifflexington.com
Phone: (800) 628-2100 ext. 705
Country: United States
Website: https://cardifflexington.com/
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Photos: (Click photo to enlarge)
Source: CorporateAds
Read Full Story - Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX | More news from this source
Press release distribution by PRLog
